SYNERGY MEGATRON™

Everolimus-Eluting Platinum Chromium Coronary Stent System

SYNERGY™ BP Stent Clinical Overview

The SYNERGY Bioabsorbable Polymer (BP) Stent Platform has been studied in over 35,000 patients across various patient and lesion complexities.

Explore

 

Heal With Confidence: Leading in Complex Patients

SYNTAX II Trial
The SYNTAX II Trial utilizing the SYNERGY BP Stent, physiological assessment, IVUS guidance, and contemporary state-of-the art PCI techniques demonstrated CABG-like outcomes in patients with three-vessel disease at 3-years.*†¹

Low rates of revascularization, peri-procedural MI, and acute ST suggests that contemporary technologies might help in reducing procedural related complications.

Heal With Confidence: Leading in Complex Patients
 

Consistently Low ST Rates

Kang Network Meta-Analysis
SYNERGY BP Stent ranked #1 for the lowest relative risk of def/prob ST At 1-year. §²
 
Kang Network Meta-Analysis
SCAAR Registry
Lowest ST rate compared to newer generation DES (n-DES) despite use in patients with statistically more Class B2/C lesions, diabetes, prior PCI, and 3VD.* **³
 
SCAAR Registry
 

Leading On Studying Short DAPT

Supporting well-constructed prospective Short DAPT clinical trials with over 5,000 patients to study the SYNERGY™ BP Stent in various complex patient populations
EVOLVE Short DAPT Trial: Primary Endpoint Results 12 Months Post-DAPT Discontinuation
Studies the safety of discontinuing DAPT at 3-months in high bleeding risk patients using the SYNERGY BP Stent.
 

ARC definite/probable ST
vs. performance goal4

0.2% ST Rate

ARC definite/probable ST vs. performance goal chart

Adjusted death/MI with 3-month DAPT
vs. historical control5

Non-Inferior

Adjusted death/MI with 3-month DAPT vs. historical control chart
 
SENIOR Trial: Safety Data at 2-Years
The SYNERGY BP Stent continued to show superior results versus REBEL BMS with short BMS-like DAPT regimen at 2-years.

All patients6

All patients chart

1-month DAPT discontinuation cohort§§ 6

1-month DAPT discontinuation cohort
 

 
Product Overview

Product Overview

Discover best-in-class strength, unmatched overexpansion, maximum visibility and uniform lesion scaffolding.

Button
Mega Strength

Mega Strength

Learn why we created a stent purpose-built for large proximal vessels.

Button
Optimal Healing

Optimal Healing

Find out how synchronous drug elution and polymer absorption enables early healing.

Button
 
Top